Stuart Curbishley

Stuart Curbishley

Company: University of Birmingham

Job title: Senior Research Fellow


Stuart was awarded his PhD by the University of Birmingham in 2005 after which his group developed a programme of immune based therapies for liver disease and liver cancer.  Backed by a successful National Institute for Health Research (NIHR) Biomedical Research Unit (BRU), he has undertaken a variety of first-in-man early phase clinical trials.  As the senior scientist within the BRU, Stuart led the development of cell therapy based around dendritic cell vaccination for primary liver cancer.  Following this success, the University invested in the building and licencing of an ATMP manufacturing facility which Stuart now directs.   The Advanced Therapies Facility manages the development of new ATMPs, both within the University of Birmingham and with UK and international partner organisations and is part of the UK government funded Advanced Therapies Treatment Centre programme.  This initiative is tasked with developing streamlined manufacturing, logistics, and clinical pathways to improve access to ATMPs for patients within the National Health Service.  Birmingham, in partnership with other Midlands institutions and NHS Wales is one of three specialist centres in the UK.



The Challenges of Manufacturing & Distributing Advanced Therapies: From Small Scale to Licensing Studies 11:30 am

Translating early research into first in man clinical trials Challenges of manufacturing Treg therapies utilizing closed system flow sorting Consider the next steps for scale up to pivotal studies and market authorization Logistics of delivering ATMPs on a global scaleRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.